



OPEN

Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53

Jacques Fantini^{1✉}, Fodil Azzaz¹, Anaïs Aulas², Henri Chahinian¹ & Nouara Yahi¹

We propose a new concept for the treatment of Parkinson's disease (PD), which considers that its root cause, α -synuclein, is an intrinsically disordered protein (IDP) difficult to target by classic approaches. Upon binding to lipid raft gangliosides, α -synuclein shifts from random coil to α -helix, forming Ca^{2+} -permeable oligomeric pores triggering a neurotoxicity cascade. We used the α -synuclein-ganglioside interaction as guideline to design a therapeutic peptide (AmyP53) that combines the respective flexible ganglioside-binding domains of α -synuclein and Alzheimer's β -amyloid protein. AmyP53 is an adaptive peptide, the first representant of a new therapeutic class. It acts as a competitive inhibitor of α -synuclein oligomer formation in brain cell membranes and prevents subsequent downstream synaptotoxicity, including the loss of dopaminergic neurons in an animal α -synuclein injection model of PD. It is active against both wild-type and mutant forms of α -synuclein. AmyP53 is administered intranasally without side effects. This new concept "target the target (gangliosides), not the arrow (IDP)" is distinct from classic α -synuclein centric approaches that did not cure PD so far.

Keywords Parkinson, Alzheimer, Synucleopathies, Therapy, Lipid raft, Ganglioside, IDP, Adaptive peptide, Pore-like annular oligomer, Calcium homeostasis

Parkinson's disease (PD) is a neurological disorder which affects both the central and peripheral nervous systems. It is characterized by a progressive loss of nigrostriatal dopamine neurons and is associated with a broad spectrum of motor and non-motor symptoms¹. PD is the second most common neurodegenerative disease after Alzheimer's disease (AD) and its prevalence will continue to grow exponentially as the population ages². The burden of PD could exceed 17 million people worldwide by 2040^{2,3}.

Despite significant efforts, there are no disease-modifying treatments addressing the root causes of PD and its primary development^{4,5}. The current therapeutic for PD patients is centered on the dopaminergic system, according to the typical loss of dopaminergic neurons in this disease⁶. However, dopamine-based drugs do not block nor even slow down disease progression⁷. Clearly, there is an urgent need for innovative therapies that tackle the root causes of PD. In this respect, α -synuclein induced neurotoxicity is the most promising target, based on a wide range of proofs that identify this protein as the principal culprit in PD and related diseases referred to as synucleopathies^{8–10}. α -synuclein is a 14.5 kDa protein with lipid-binding properties¹¹. It is expressed in the brain and chiefly located in synaptic terminals¹². Its main physiological function is generally thought to mediate vesicular trafficking at the neuronal membrane¹³, control synaptic plasticity and regulate neurotransmitter release¹⁴. Extracellular α -synuclein¹⁵ can also bind to the plasma membrane of brain cells and then self-assemble into neurotoxic oligomers^{16–18}. Correspondingly, the oligomerization of α -synuclein in the plasma membrane of brain cells is considered as a primary cause of PD¹⁸. Indeed, membrane-associated α -synuclein oligomers (amyloid pores)^{19,20} trigger a cascade of neurotoxicity events involving dysregulated Ca^{2+} influx and eventually the loss of dopaminergic neurons that are involved in motor process control, a hallmark of PD.

Conceptually, it seems easy to neutralize α -synuclein, but the task proved to be more challenging than anticipated. α -synuclein belongs to the category of proteins called intrinsically disordered proteins (IDPs) that can adopt myriads of distinct conformations in solution^{21–24}. However, when bound to the membrane, the protein typically adopts an α -helical conformation²⁵, which is the starting point of the oligomerization process

¹Aix Marseille Univ, INSERM UA16, Marseille, France. ²AmyPore, Septèmes-les-Vallons, France. ✉email: jacques.fantini@univ-amu.fr

into Ca^{2+} permeable amyloid pores¹⁸. Indeed, IDP's toxicity has been associated with the ability of these proteins to bind to biological membranes²⁶ and induce membrane damage^{27–29}.

Membrane lipids, especially gangliosides and cholesterol, play a critical role in amyloid pore formation which occurs in lipid rafts³⁰. In fact, gangliosides act as molecular chaperones able to convert a disordered extracellular α -synuclein into a structured protein³¹ displaying a functional ganglioside binding domain (amino acids 34–45)³² surrounded by two α -helix domains, one of which includes a cholesterol binding domain (amino acids 67–78)³³. Then, the protein penetrates the membrane, interacts with cholesterol and oligomerizes into amyloid pores through a cholesterol-controlled mechanism^{34,35}. Because they mediate a dysregulated entry of Ca^{2+} ions in target cells, amyloid pores can be considered as the root cause of PD and a privileged target for innovative therapies¹⁸. One possible approach is to block the initial binding of α -synuclein monomers to plasma membrane gangliosides. However, there are two pitfalls in this strategy. (i) As other amyloid proteins such as Alzheimer's β -amyloid protein ($\text{A}\beta$), α -synuclein does not bind to a single ganglioside molecule but rather selects a cluster of gangliosides with a high dynamic at the edge of lipid rafts³⁶. In other words, the target of α -synuclein is not stable but in motion. (ii) As a typical IDP, α -synuclein undergoes a gradual structuration upon binding to gangliosides, meaning that membranes act as a catalyst for the formation of neurotoxic oligomers^{37,38}. This striking property must be considered for the development of a blocking therapeutic compound. This definitely excludes small organic compounds, usually polycyclic, which are far too rigid and locked in a stable conformation^{18,39}. To overcome this problem, we designed a synthetic peptide derived from the common ganglioside binding domain of α -synuclein and $\text{A}\beta$ ⁴⁰. This peptide, called AmyP53, displays striking structural adaptive properties. It is specific enough to ignore neutral glycolipids while sufficiently plastic to interact with the main ganglioside species expressed in human brain (GM1, GM3, GD1a, GD1b, GT1b) that are recognized (yet with distinct specificities) by $\text{A}\beta$ ^{41,42} and α -synuclein^{32,43–46}. The therapeutic effect and mechanism of action of AmyP53 in AD models have been recently published by our group^{36,47,48}. Here we present parallel data on the molecular mechanism of action and the therapeutic efficiency of AmyP53 in several PD models. These new data confirm the unique therapeutic potential of AmyP53 and further demonstrate that it is applicable to PD.

Results

Interaction of AmyP53 and α -synuclein with GT1b ganglioside

Previous studies have shown that α -synuclein interacts with brain gangliosides, including GM1, GM3 and GT1b^{32,43}. In the present study, we selected GT1b because this ganglioside can form (i) stable monolayers that are compatible with microtensiometry measurements and (ii) micellar solutions that are compatible with circular dichroism analysis⁴⁹. First, we studied the interaction of wild-type α -synuclein and AmyP53 with reconstituted monolayers of GT1b. In these experiments, the protein-ganglioside interaction is detected by an increase of the surface pressure measured by a microtensiometer at the air-water interface. The data indicated that AmyP53 interacts with the gangliosides at concentrations significantly lower than wild-type α -synuclein (Fig. 1). The logistic curve fitting allowed to estimate the EC_{50} (concentration that gives half-maximal response) for AmyP53 at $0.52 \pm 0.08 \mu\text{M}$ compared with $1.78 \mu\text{M} \pm 0.15 \mu\text{M}$ for wild-type α -synuclein. As shown in Table 1, mutant α -synucleins also recognized the ganglioside membrane, yet with distinct characteristics. The EC_{50} values were statistically significant between AmyP53 and all α -synuclein proteins, and between wild-type and mutant α -synucleins. Overall, these experiments confirmed the higher avidity of AmyP53 for the ganglioside membrane compared with wild-type and mutant forms of α -synuclein.

AmyP53 is a competitive inhibitor of α -synuclein binding to ganglioside GT1b

In addition to being able to recognize GT1b monolayers at a lower concentration than α -synucleins, AmyP53 also interacts with these monolayers faster than these proteins. The initial velocity of AmyP53 for GT1b binding is $0.89 \pm 0.03 \Delta\pi.\text{min}^{-1}$, compared with $0.51 \pm 0.04 \Delta\pi.\text{min}^{-1}$ for wild-type α -synuclein (Fig. 2A). When both AmyP53 and α -synuclein were added simultaneously to the GT1b monolayer, the kinetics of interaction was similar to that of AmyP53, with an initial velocity of $0.82 \pm 0.05 \Delta\pi.\text{min}^{-1}$. These data indicate that AmyP53 wins the race for the occupation of a GT1b raft-like membrane when present in competition with α -synuclein. Figure 2B shows the electrostatic surface potential of α -synuclein, especially the 34–45 fragment which shares 10 on 12 amino acids with AmyP53⁴⁰. It can be observed that AmyP53 is globally more electropositive than the 34–45 motif of α -syn. This unique feature gives a kinetic advantage allowing AmyP53 to reach the electronegative surface of raft gangliosides faster than α -synuclein. Its short size may also help speed up the diffusion rate of AmyP53. Both effects may explain why AmyP53 wins the binding competition for lipid rafts.

Then we used molecular dynamics simulations to evaluate how fast AmyP53 interacts on the surface of a lipid raft compared to α -synuclein. The initial conformation presented in Fig. 3 shows that α -synuclein and AmyP53 are placed at a similar height above the polar part of GT1b molecules. Only 2 ns of simulation were sufficient to observe the first contact between AmyP53 and the sugar moiety of GT1b molecules while α -synuclein barely moved along the z axis. Then, AmyP53 extensively interacts with the lipid raft after 7 ns of simulation.

AmyP53 structuration upon GT1b binding

AmyP53 is 12-mer peptide designed by combining the ganglioside-binding domains of α -synuclein and $\text{A}\beta$. This peptide is highly soluble in water (up to 150 mM)⁴⁷. We performed a circular dichroism (CD) analysis to determine whether AmyP53 adopts a stable conformation in solution. The CD spectrum of AmyP53 in water solution does not reveal any specific structure; no α -helix, no β -turn (Fig. 4, blue spectrum). Thus, AmyP53 can be considered as a disordered peptide. However, in presence of GT1b micelles, the peptide undergoes a typical β -turn conformation demonstrated by the presence of a positive band at 202 nm and a negative band at 224 nm, (Fig. 4, red spectrum). For comparison we showed the circular dichroism spectrum of the Cyclo(VPGG)₄ peptide, which is a reference for β -turn identification by circular dichroism⁵⁰. These data, which confirmed




Fig. 1. Interaction of wild-type α -synuclein proteins and AmyP53 with GT1b ganglioside monolayers. Monolayers of ganglioside GT1b were prepared at the air-interface at an initial surface pressure of 17.5 mN/m. After equilibrium, wild-type (wt) or or AmyP53 was added in the aqueous subphase underneath the monolayer at the indicated concentrations. Surface pressure measurements were recorded in real-time until reaching a plateau value, typically after 1 h of incubation. The values correspond to the maximal surface pressure increase measured when the system has reached a state of equilibrium. The data are expressed as mean \pm SD of three independent experiments. A logistic fit was applied to each curve.

that AmyP53 physically interacts with GT1b, showed that AmyP53 adopts a turn conformation in presence of GT1b. Molecular dynamics simulations fully confirmed this conformational adaptation (Fig. 5). Under initial conditions, a disordered conformer of AmyP53 is placed above the central area of the raft. Very rapidly, the N-terminal amino acid K1 dives into the raft, initiating the interaction. In subsequent steps, the peptide first adopts a broken conformation (at 12 ns), then migrates to the periphery of the raft and adopts a typical turn conformation (at 50 ns). Our in-silico data also allowed to identify the key amino acid residues involved in AmyP53 binding to GT1b, i.e. K1, Y6, H9 and K12.

AmyP53 blocks the formation of Ca^{2+} permeable amyloid pores formed by α -synuclein oligomers in aged brain cells

Then we evaluated the protective effect of AmyP53 in late passage SH-SY5Y cells which mimic aged brain cells³⁶. The cells were loaded with the permeant fluorescent dye Fluo-4AM which labelled the intracellular calcium, then incubated with α -synuclein with or without AmyP53. Amyloid pores formed by the oligomerization of α -synuclein are functionally detected by measuring the intracellular concentration of Ca^{2+} ions visualized by increased intensity of the Fluo-4AM labelling. As shown in Fig. 6A, a massive entry of calcium was detected in the cells incubated with α -synuclein. In contrast, the cells incubated with the α -synuclein/AmyP53 mixture have a stable and low calcium level. The statistical analysis of these data confirmed the protective effect of AmyP53 in this cellular model of PD (Fig. 6B). The kinetics of Ca^{2+} entry in cells incubated with α -synuclein alone or with

Peptide or protein	EC ₅₀ (μM ± SD)
AmyP53	0.53 ± 0.08
α-synuclein (wild-type)	1.78 ± 0.15
α-synuclein (A30P mutant)	1.05 ± 0.05
α-synuclein (E46K mutant)	1.18 ± 0.11
α-synuclein (A53T mutant)	1.08 ± 0.08

Table 1. Comparison of the ganglioside-binding properties of AmyP53, wild-type and mutant α-synucleins. Monolayers of ganglioside GT1b were prepared at the air-interface at an initial surface pressure of 17.5 mN/m. After equilibrium, AmyP53, the wild-type (wt) or the indicated mutant α-synuclein protein was added in the aqueous subphase underneath the monolayer at several concentrations (0.1–10 μM range). Surface pressure measurements were recorded in real-time until reaching a plateau value. The EC₅₀ values (mean ± SD) were calculated from four independent measurements ($p < 0.05$ between AmyP53 and all α-synuclein proteins, and between wild-type and mutant α-synucleins in ANOVA test and post-hoc analysis).




Fig. 2. AmyP53 is a competitive inhibitor of α-synuclein binding to ganglioside GT1b. (A) The values of the histograms are indicated as the mean ± SD ($p < 0.05$ between AmyP53 and α-synuclein, no statistically significant difference between AmyP53 and AmyP53/α-synuclein competition in the Student's t-test). (B) Electrostatic surface potential of α-synuclein (from pdb 1qx8), and AmyP53 (blue, electropositive; red, electronegative). The position of amino acid residues 34–45 in full length α-synuclein is indicated by a rectangle. The amino acid sequences of AmyP53 and α-synuclein fragment 34–45 are indicated.

the α-synuclein/AmyP53 mixture showed that the protective effects of AmyP53 against formation of amyloid pores were observed at any time during the 75-min of the assay (Fig. 6C). A control experiment without any treatment confirmed that the baseline is stable during the recordings. Most importantly, AmyP53 by itself did not affect intracellular Ca^{2+} levels (Fig. 6C). Thus, its efficacy to prevent the increase of intracellular Ca^{2+} induced by α-synuclein can be attributed to its capacity to block the formation of Ca^{2+} -permeable α-synuclein oligomers in the plasma membrane of aged brain cells. Finally, we tested the capacity of AmyP53 to prevent the formation of such oligomeric pores by mutant forms of α-synuclein (A30P, E46K, A53T) in the same model of aged brain cells (Fig. 6D). All three α-synuclein mutant proteins readily induced an increase of intracellular Ca^{2+} that could be detected by Ca^{2+} imaging with Fluo-4AM labelling. Interestingly, A30P was the most effective compared with the wild-type and the two other mutant forms of α-synuclein (Fig. 6, inset). In all cases, AmyP53, used in competition at equimolar concentrations, abrogated the effect for all mutants. Taken together, these data




Fig. 3. Competition between α -synuclein and AmyP53 to interact with the polar surface of the lipid raft. α -synuclein is depicted as green surface, AmyP53 is depicted as blue surface, gangliosides are depicted as orange spheres and POPC are depicted as thin lines colored by atom names (carbon in cyan, hydrogen in white, oxygen in red, nitrogen in blue and phosphorus in brown).

demonstrate that AmyP53 has broad anti-oligomer properties that affect amyloid pore formation induced by both wild-type and mutant α -synuclein proteins.

Therapeutic efficiency of AmyP53 in an animal α -synuclein injection model of PD

Finally, a study (Fig. 7A) was designed to investigate the therapeutic effects of AmyP53 in an aged mouse model of PD induced by stereotaxic injection of α -synuclein protofibrils (containing at least 50% of oligomers as detailed in Materials and Methods) into the substantia nigra pars compacta (SNpc)⁵¹. This model reproduces the loss of dopaminergic neurons in the nigra striata area that is an essential neuropathological feature of PD.

A preliminary assessment of the safety of AmyP53 injection into the SNpc was carefully conducted on 5 mice (Fig. 7B) before starting the complete experimental study which involved 7 mice per group. Administration of AmyP53 followed the design planned for α -synuclein-treated mice. AmyP53 was given intranasally, and 10 min after this administration, mice were subjected to stereotaxic surgery to inject AmyP53 in the SNpc. Mice were then treated with AmyP53 for 7 consecutive days (intra-nasal administration daily). Recovery from surgery was good and mice behaved normally during the whole experiment. Body mass was also stable (Fig. 7B). Altogether, the results of this preliminary step indicated that AmyP53 is safe.

Based on these safety results, we proceeded with the whole experiment which started with the injection of α -synuclein protofibrils into the SNpc and ended with the analysis of dopaminergic neurons after 35 days. Three groups of 7 animals were studied: (i) one group injected with vehicle alone, (ii) one group injected with α -synuclein protofibrils, and (iii) one group co-treated with α -synuclein protofibrils and AmyP53 (an intracerebral administration of AmyP53 co-injected with α -synuclein protofibrils was followed by daily treatment by the intranasal route). Under these conditions, AmyP53 did not display any significant effect on the body weight of the treated mice (Fig. 7C) and did not induce any negative impact on their overall behavior, throughout the 35-day treatment period. At the end of the treatment, animals were euthanized, brains were extracted, fixed, and labelled for tyrosine hydroxylase (TH) present in dopaminergic neurons (Fig. 8). While a strong TH signal is observed in the control group (Fig. 8A), α -synuclein injection significantly decreased the immunolabeling of dopaminergic neurons (Fig. 8B). This phenotype is representative of the loss of dopaminergic neurons. AmyP53 induced a protective effect on dopaminergic neurons as demonstrated by the analysis of TH + cells in brain slices from animals exposed to α -synuclein protofibrils and treated with AmyP53 (Fig. 8C). Direct comparison between α -synuclein-treated mice with or without AmyP53 treatment indicated a statistically beneficial effect of AmyP53 on the survival of dopaminergic neurons at day 35 (Fig. 8D, E). This effect was observed by counting the number of TH + neurons (Fig. 8D) and by measuring the intensity of TH immunolabeling (Fig. 8D) in representative microscopic fields.




Fig. 4. Circular dichroism analysis of AmyP53 structuration upon GT1b binding. AmyP53 was tested in absence (blue curve) or in presence (red curve) of GT1b micelles. The spectrum of Cyclo(VPGG)₄, a β -turn reference, is colored in grey. Note that AmyP53 (in presence of GT1b) and the reference have a similar peak at 202 and 205 nm, respectively.

Primary observation (Irwin) test in rodents does not reveal any effect of AmyP53 on behavior and physiological function

Considering that AmyP53 has no effect by itself on intracellular Ca^{2+} levels (Fig. 6C), the protective effect demonstrated in a rodent model of PD (Fig. 8) suggests that the peptide acts by blocking the neurotoxic cascade




Fig. 5. Conformational flexibility of AmyP53 during its interaction with a GT1b raft. The initial conditions of the system are shown in the left panel. A disordered conformer of AmyP53 is placed above the central area of the raft. The snapshots illustrate how AmyP53 changes its conformation to dive into the raft at its N-terminal amino acid K1 (4.3 ns). At 12 ns, it adopts a kinked conformation allowing the amino acids K1 to Y6 to spread on the raft surface. At 50 ns AmyP53 migrated to the periphery of the raft while adopting a typical turn conformation.

induced by α -synuclein oligomers. However, it was important to ensure that the peptide did not cause any physiological changes at the brain level. Thus, we evaluated the potential effects of AmyP53 on brain functions by the primary observation test (Irwin Test)⁵². Behavioral modifications, physiological and neurotoxicity symptoms, rectal temperature and pupil dilation or contraction were recorded according to a standardized observation grid derived from that of Irwin observation time-points (15 min, 30 min and 1, 2, 4, 6 h and 24 h after intranasal administration of AmyP53 at 0.1, 1.0 and 5.0 mg/kg body weight). Treatment with AmyP53 (6 rats) did not produce any significant effect on the primary observation Irwin test (Table 2). These data showed that AmyP53 has no effect by itself on neurobehavioral functions associated with excitation, sedation, stereotypy, motor-coordination, autonomic and pain. Thus, its protective effect on the loss of dopaminergic neurons in the animal model of PD (Fig. 8) can be attributed to its ability to block the neurotoxic cascade induced by α -synuclein oligomers.

Preclinical studies of AmyP53 further demonstrate its total safety in two animal models

Brain ganglioside composition changes between mammal species. To perform reliable drug toxicity test, we needed to choose animal species whose brain ganglioside composition is similar to humans. Careful analysis of the literature suggested that rodents and rabbits are the most reliable species for our study³⁰. We thus analyzed the binding of AmyP53 to rat and rabbit brain gangliosides. After extraction and purification from brain tissues, gangliosides were spread as monolayers at the air-water interface and incubated with AmyP53 added in the aqueous subphase. As shown in Fig. 9, AmyP53 efficiently interacted with brain gangliosides purified from rats or rabbits. For comparison, we performed a similar analysis with gangliosides extracted from human red blood cells which, like the human brain, expresses GM1⁵³ and GM3⁵⁴. These gangliosides are also recognized by amyloid proteins, including A β and α -synuclein⁴⁰. Thus, as expected from the beneficial effects of AmyP53 in cellular human models, the peptide recognized these gangliosides of human origin (Fig. 9). Overall, the capacity of AmyP53 to recognize human, rat and rabbit gangliosides validated the choice of these two animal species for further toxicology studies.

A summary of toxicology data is presented in Table 2. Repeated intranasal administration of AmyP53 to male and female rats for 28 days and 14 days of recovery after cessation of the treatment, at dose levels of 0.1, 1.0 and 5.0 mg/kg body weight/day was well tolerated and did not cause any symptoms indicative of local and/or systemic toxicity. Histological analysis did not reveal any abnormality. Cardiorespiratory analysis after intranasal administration of AmyP53 at the highest dose (5 mg/kg BW) also revealed no abnormality.




Fig. 6. AmyP53 prevents the formation of Ca^{2+} permeable amyloid pores by wild-type and mutant forms of α -synuclein. (A) Aged SH-SY5Y cells (> 10 passages in culture) were loaded with the Ca^{2+} indicator Fluo-4 AM and then incubated with 220 nM of α -synuclein with or without 220 nM AmyP53 as indicated. The micrographs taken after 75 min of incubation showed that the increase in intracellular Ca^{2+} induced by α -synuclein (warm colors, yellow/red) was strongly inhibited by AmyP53 (cold colors, blue). Scale bars: 100 μm . (B) Student's t-test was used to compare the statistical significance on calcium dependent fluorescence after α -synuclein treatment between control and AmyP53 conditions ($p < 0.001$). (C) Kinetics of Ca^{2+} fluxes induced by α -synuclein (220 nM) in absence (black curve) or presence of AmyP53 (220 nM) (grey curve). Control experiments with AmyP53 (220 nM) alone (red curve) or without any treatment (green curve) are shown for comparison (\pm SEM, $n = 110$ cells). (D) Cells incubated with mutant proteins alone, respectively A30P, E46K, and A53T (220 nM), or incubated with both mutant proteins and chimeric peptide (both 220 nM), respectively A30P + AmyP53, E46K + AmyP53, and A53T + AmyP53. The micrographs taken after 75 min of incubation showed that the increase in intracellular Ca^{2+} induced by mutant forms of α -synuclein (warm colors, yellow/red) was strongly inhibited by AmyP53 (cold colors, blue). Scale bars: 100 μm . Student's t-test was used to compare the statistical significance on calcium dependent fluorescence after each mutant α -synuclein treatment between control and AmyP53 conditions ($p < 0.001$). A table summarizing the inhibitory effect of AmyP53 on Ca^{2+} fluxes induced by wild-type and mutant forms of α -synuclein (expressed as mean \pm SEM, all experiments performed in triplicate) is shown in inset.

AmyP53 was also repeatedly administered intranasally to male and female rabbits during 14 days at dose levels of 0.1, 1.0 and 5.0 mg/kg body weight/day. The results showed no systemic or local toxicity during the in vivo phase of the study or at post-mortem. The dose level of 5.0 mg/kg/day was considered the No Observed Adverse Effect Level (NOAEL) for the intranasal route in both rats and rabbits (Table 2). Finally, the bacterial reverse mutation assay (Ames test, modified for histidine-containing peptides), which detects potential genotoxicity⁵⁵, was negative (Table 2).

Physicochemical characteristics and metabolic stability of AmyP53 in vitro

To assess the suitability of AmyP53 for further drug development, we tested its metabolic stability in plasma and its binding to plasma proteins. First, 1 μM AmyP53 was incubated at 37 $^{\circ}\text{C}$ for various times (0–4 h) with plasma from rat, rabbit, mini-pig and dog. The stability of AmyP53 was determined by measuring the amount of intact compound by liquid chromatography-mass spectrometry (LC-MS). The data indicated a very good metabolic stability with half-life times of 83 min (dog), 364 min (mini-pig), 601 min (rabbit) and 787 min (rat) (Table 3). For comparison the half-life times of propantheline, an antimuscarinic agent used for the treatment of enuresis⁵⁶, used here as a control, were 104 min (dog), 179 min (mini-pig), 17 min (rabbit) and 227 min (rat) (Table 3). These data are consistent with the design of AmyP53 which lacks consensus proteolytic sites for human plasma proteases (https://web.expasy.org/peptide_cutter/ as accessed on October 1st 2024).

Second, we analyzed the binding of AmyP53 to plasma proteins of the same four animal species (rat, rabbit, dog, mini-pig) by rapid equilibration dialysis (RED), compared with propranolol. After 2 h of incubation at





Fig. 7. Assessment of AmyP53 safety in mice. **(A)** Experimental protocol. Three groups of 7 animals were studied: control (injection with vehicle), treated with α -synuclein protofibrils, treated with both α -synuclein protofibrils and AmyP53. AmyP53 was then injected intranasally daily in the third group for 35 days. **(B)** Preliminary assessment of the effect of intracerebroventricular injection of AmyP53 alone followed by 7-day intranasal treatment on mouse body weight (the data show the body weight of each animal separately). There is no statistically significant body weight variation for any animal treated with AmyP53 (Student's t-test, $p < 0.05$). **(C)** Lack of significant variations in body weight between the three groups of animals during the experiment (35 days). Data are expressed as mean \pm SD, $n = 7$.

37 °C, the bound fraction of AmyP53 ranged from $81.7 \pm 0.8\%$ (rabbit) to $93.4 \pm 0.6\%$ (rat) (Table 3). These data showed that a large proportion of AmyP53 binds to plasma proteins, which may contribute to increase its stability in vivo and improve its biodistribution as already shown for therapeutic drugs including peptides^{57–59}. These stability studies are consistent with the pharmacokinetics parameters of AmyP53 administered intranasally in rats (Table 4). Under these conditions, AmyP53 is detected for several hours in the brain with a T_{max} of 5 min and a $t_{1/2}$ of 61 min⁴⁷.

Discussion

There is currently no effective treatment for PD. We propose here an innovative strategy based on a paradigm change. On one hand, in contrast with symptomatic approaches, we tackle the earliest step in the neurotoxicity cascade induced by α -synuclein oligomers that are now considered as a marker and responsible for PD development^{60,61}. This is thus a disease-modifying strategy. On the other hand, in contrast with immunotherapies directed against the different forms of α -synuclein (monomeric, oligomeric, fibrils) we do not develop an α -synuclein centric approach because α -synuclein fulfills important physiological functions^{62–71} that need to be preserved upon treatment. We thus must be very cautious with therapeutic strategies targeting α -synuclein. In particular, non-pathological α -synuclein controls a number of critical regulatory functions associated with neural plasticity⁷², synaptic vesicle recycling, dopamine release, exocytosis and endocytosis, vesicular trafficking, interaction with SNARE proteins, and roles in lipid/fatty acid metabolism and transport^{73–76}. Apart from these functions, non-pathological α -synuclein is reported to interact with a wide range of intracellular membranes, which is suggested to be relevant for its normal physiological roles⁷⁷. Thus, it is reasonable to think that an abnormal membrane interaction could lead to neuronal dysfunction and cell death.



The poor specificity of anti- α -synuclein antibodies works against their use in clinics. Indeed, Kumar et al.⁷⁸ studied a panel of 16 anti- α -synuclein antibodies using distinct experimental approaches, including single molecule assays, surface plasmon resonance, and immunoblotting. This study clearly showed that all the antibodies claimed to be 'oligomer/conformation-specific' cannot distinguish between oligomeric, fibrillar and monomeric α -synuclein. The reason for this lack of specificity emanates from the disordered nature of α -synuclein which belongs to the class of IDPs. The conformations adopted by α -synuclein in the oligomeric, prefibrillar and/or fibrillar forms can probably preexist in the myriads of conformations of the monomeric protein. If one of these conformers is recognized by an antibody, then this antibody will bind to all multimeric forms in which this conformer is present. Thus, this explains why it is potentially impossible to obtain antibodies that bind specifically to a given form of α -synuclein and totally ignore the other forms.

◀ **Fig. 8.** AmyP53 is active against the loss of dopaminergic neurons induced by α -synuclein protofibrils injected into the brain of aged living mice. AmyP53 rescues dopaminergic neurons loss induced by α -synuclein protofibrils at day 35 after model induction. (A–C) Representative TH immunolabeling of similar brain slices from animals treated with vehicle alone (A), α -synuclein protofibrils (B) and both α -synuclein protofibrils and AmyP53 (C) are shown. Scale bars: 400 μ m. (D) Number of TH+ (dopaminergic neurons) at day 35 in the three experimental conditions (control, i.e. vehicle), oligomers (α -synuclein protofibrils) and + AmyP53 (injection of α -synuclein protofibrils in presence of AmyP53, then daily intranasal treatment by AmyP53). (E) The intensity of TH labeling was measured in distinct representative microscopic fields of similar slices at the same magnification. In (D) and (E) the data are expressed as mean \pm SD ($p < 0.05$ between control/oligomers and oligomers/AmyP53 conditions in One-Way ANOVA test and post-hoc analysis). In (E) the micrographs show representative similar fields of TH immunolabeling of brain slices from animals treated with vehicle alone (control), α -synuclein protofibrils (oligomers) and both α -synuclein protofibrils and AmyP53 (+ AmyP53) are shown. Scale bars: 50 μ m.

Study	Test system or animal species	Study design	Doses	Results
Ref. B-03767 Safety pharmacology study for behavioural effects of AmyP53 using the primary observation (Irwin) in Sprague Dawley rats	Irwin test in rats GLP	Single intranasal administration of AmyP53 or reference item (Morphine 8 mg/kg)	3 doses 0.5, 1 and 5 mg/kg body weight (BW)	AmyP53 did not induce any relevant neurologic adverse effects related with neuro-behavioural functions associated with excitation, sedation, stereotypy, motor-coordination, autonomic and pain
Ref. 20230069SPCP Evaluation of effects on cardiac and respiratory functions in conscious rats following single intranasal administration	Evaluation of cardiac and respiratory functions and activity level analyzed by telemetry jackets on Wistar rats	Single intranasal administration of AmyP53 Recordings during a 24 h-period	1 dose 5 mg/kg BW	AmyP53 administered by the intranasal route did not induce any statistically significant change on the cardiac and respiratory function, and activity level.
Ref. AMYPORE/P3-T-0719/AmyP53/IV-IN/v1 Determination of the maximum tolerated dose of AmyP53 administered by intravenous and intranasal routes in rats	Assessment of the MTD of AmyP53 injected intravenously or intranasally in female Wistar rats GLP	Evaluation criteria: body weight, mean body weight change, behaviour and macroscopic autopsy of rats	Increasing doses ranging from 0.128 to 80 mg/kg BW (intravenous) or 0.0064 to 4 mg/kg BW (intranasal route) every two days between D1 and D9	The maximal tolerated dose (MTD) of AmyP53 in female Wistar rats is greater than 80 mg/kg for the intravenous route and greater than 4 mg/kg BW for the intranasal route.
Ref. AMYPORE/P4-T-0919/AmyP53/DRF-IN/v1 Determination of the dose range finding of AmyP53 administered by intranasal route in rats	Assessment of the DRF of AmyP53 injected intranasally in male and female Wistar rats GLP	Evaluation criteria: body weight, mean body weight change, food consumption, hematology, coagulation time, blood chemistry, histological analysis of organs and macroscopic autopsy of behaviour of rats	3 doses 0.2, 1 and 5 mg/kg BW every two days during five days	The maximal intranasal dose of AmyP53 without any signs of toxicity or dysfunction, is greater or equal to 5 mg/kg BW in both male and female Wistar rats.
Ref. B-03766 28-Day repeated dose toxicity of the test item AmyP53 after intranasal administration to male and female rats	Toxicology and toxicokinetics studies of AmyP53 injected intranasally in male and female Sprague Dawley rats GLP	Evaluation criteria: observation of local reaction, mortality, systemic clinical signs, body weight and food consumption, clinical pathology determinations, ophthalmic exams, organ weight, hematology, histopathological evaluation of a full list of tissues.	3 doses 0.2, 1 and 5 mg/kg BW every day for 28 days followed by 14 days of recovery	The intranasal no-observed adverse effect level (NOAEL) was established at the highest actual dose level tested, 5 mg/kg BW/day
Ref. 23P0122 14-Day repeated tolerability/toxicity study in rabbits by intranasal route with a 14-day recovery period and toxicokinetics	Toxicology and toxicokinetics studies of AmyP53 injected intranasally in male and female New Zealand White rabbits GLP	Evaluation criteria: observation of local reaction, mortality, systemic clinical signs, body weight and food consumption, clinical pathology investigations, ophthalmoscopy, organ weight, hematology, coagulation, clinical chemistry, histopathological evaluation of a full list of tissues.	3 doses 0.2, 1 and 5 mg/kg BW every day for 28 days followed by 14 days of recovery	AmyP53 did not induce toxicity and is well tolerated after repeated intranasal administrations in rabbits at dose levels of 0.1, 1 and 5 mg/kg BW/day, therefore the dose level of 5 mg/kg BW/day is considered the No Observed Adverse Effect Level (NOAEL).
Ref. PCA-03 A-21001 Genotoxicity assay: Ames test following the OECD 471	Genotoxicity Ames test	Bacterial Reverse mutation test following the OECD 471 and the ICH guideline S2 (R1)	6 doses (4.69 to 150 μ g)	AmyP53 did not cause a positive mutagenic response

Table 2. Summary of preclinical in vivo toxicology studies of AmyP53. GLP, good laboratory practices; MTD, maximal tolerated dose; DRF, dose ranging finding.

We propose to give up α -synuclein centric approaches and instead tackle the problem from a different angle. We focused on PD-related plasma membrane targets that are critical players in the formation of neurotoxic annular oligomers: the gangliosides¹⁸. Thus, modulating the membrane binding of α -synuclein is clearly a solution to design disease-modifying therapeutic drugs for PD treatment^{79,80}. In this respect, the development of drugs targeting membrane gangliosides has tremendous potential and interest⁸¹. This is the route we are opening with the adaptive peptide AmyP53.

AmyP53 is an excellent example of an adaptive peptide⁸². Its amino acid sequence is derived from a disordered motif present in two IDPs which adopts a functional loop structure during interaction with raft gangliosides. Hence, the key feature of AmyP53 is that it does not have any particular 3D structure in solution, but it folds




Fig. 9. Interaction of AmyP53 with gangliosides extracted from the brain of rats and rabbits and from human red blood cells (RBC). Gangliosides were spread as stable monolayers at the air-water surface. AmyP53 (10 μ M) was injected underneath these monolayers and the interaction was followed by measurements of the surface pressure increase (blue histograms). The grey histograms represent a control experiment without AmyP53. In all cases the data are expressed as mean \pm SD of three independent experiments (plateau values reached after 60 min of incubation). The statistical significance of the data was assessed using Student’s t-test (**, $p < 0.01$; ***, $p < 0.001$).

Matrix	AmyP53 $t_{1/2}$	Propantheline $t_{1/2}$	AmyP53 bound to plasma protein %	Propranolol bound to plasma protein %
Rat plasma	787 min	227 min	93.4 \pm 0.6	89.8 \pm 0.1
Rabbit plasma	601 min	17 min	81.7 \pm 0.8	74.8 \pm 1.1
Mini-pig plasma	364 min	179 min	81.4 \pm 0.8	85.2 \pm 0.9
Dog plasma	83 min	104 min	84.6 \pm 4.3	86.5 \pm 1.0

Table 3. Physicochemical characteristics and metabolic stability of AmyP53 in vitro.

Parameter	Value in brain tissue
Cmax (ng/mL)	1766
Tmax (min)	5
AUC 0→120 (ng.mL/min)	62794
T1/2	61

Table 4. Pharmacokinetics parameters following intranasal administration of AmyP53 in rats. Retrieved from ref⁴⁷. (published by MDPI under the terms and conditions of the Creative Commons Attribution (CC BY) license).

into a turn structure upon binding to raft gangliosides, as demonstrated by circular dichroism studies (Fig. 4) and molecular dynamics simulations (Figs. 3 and 5). When incubated in competition with wild-type or PD-associated mutated forms of α -synuclein, AmyP53 always wins the race to lipid raft gangliosides, due to its condensed electropositive surface potential. This unique property is at the basis of the potent inhibitory effect of AmyP53 on the formation of pore-like annular oligomers in the plasma membrane of brain cells (Fig. 6). It is essential to acknowledge that AmyP53 is efficient not only on wild-type but also on several mutant forms of α -synuclein (A30P, E46K, A53T) (Figs. 1 and 6) that are associated with genetically inherited PD⁸³. Under our experimental conditions, we determined that all mutant forms of α -synuclein have a higher affinity for GT1b

ganglioside monolayers, including A30P (Table 1). This result may be interpreted as surprising, given that the A30P mutant of α -synuclein is generally considered to have a lower affinity for lipid membranes compared to wild-type and other mutant forms^{84,85}. However, there are some inconsistencies in the literature between the membrane interaction of A30P and other α -synuclein proteins⁸⁶. For instance, isothermal calorimetry studies showed that A30P shared a similar binding affinity to wild-type α -synuclein in a gel phase whereas binding was weaker in the liquid crystalline phase⁸⁷. Since gangliosides also form a liquid ordered (Lo) phase⁸⁸, our binding data are consistent with these previous studies. Moreover, it has also been demonstrated that α -synuclein binds to model membranes containing anionic phospholipids in a manner that is not sensitive to the A30P mutation⁸⁹. This may also be the case for GT1b monolayers which bear a high density of electronegative charges, suggesting that electrostatic attraction might be the main mechanism controlling the interaction of α -synuclein proteins with lipid rafts. Indeed, the A30P mutation does not affect the electrostatic surface potential of the protein. Finally, in agreement with our binding data, Ca^{2+} imaging experiments (Fig. 6) revealed that the A30P mutant is also the most potent α -synuclein protein for amyloid pore formation. In this respect, the potent inhibitory effect of AmyP53 on the A30P mutant is particularly interesting. Overall, these quantitative data confirm and extend previous preliminary findings published by our group⁸³.

AmyP53 is also efficient in an animal model of PD based on the loss of dopaminergic neurons induced by α -synuclein protofibrils injected into mice brains (Fig. 8). In this study, AmyP53 was co-injected with α -synuclein to ensure that the peptide was present in the brain when α -synuclein protofibrils are injected, to optimize its effects. Then AmyP53 was administered once a day intranasally for 7 days (pre-assessment study) or 35 days (whole study). This protocol was chosen to limit the number of animals used in these experiments for ethical reasons. However, considering the relatively short half-life of AmyP53 in the brain (about 1 h)⁴⁷, it is highly likely that the initial injection of the peptide into the SNpc is not a determining parameter for the therapeutic effect. Daily administration of AmyP53 by the nose-to-brain route is definitely the protocol that we will implement for clinical trials in humans, excluding any invasive intervention. From a mechanistic point of view, the protective effect of AmyP53 in the animal model of PD was attributed to the binding of AmyP53 to brain gangliosides as demonstrated with gangliosides extracted and purified from the brain of rodents and rabbits. Indeed, AmyP53 had no effect by itself on baseline intracellular levels of Ca^{2+} (Fig. 6C). Moreover, the peptide did not induce any neurologic effects related to neurobehavioral functions associated with excitation, sedation, stereotypy, motor-coordination, autonomic and pain (Irwin test, Table 2).

AmyP53 is a membrane lipid targeted therapy that for the first time considers globally the lipid raft entity as a pharmacophore. Due to its ability to adopt several conformations during its journey on a lipid raft, AmyP53 spreads on several areas of the raft almost simultaneously, as suggested by molecular dynamics studies³⁶. Indeed, after an initial binding step in the central zone of the raft, where the electronegative field is the strongest, AmyP53 reaches peripheral zones where it can form stabilized complexes with gangliosides displaying higher flexibility. This is a critical point because the natural target of amyloid proteins such as α -synuclein are those gangliosides located at the periphery of lipid rafts where they have sufficient conformational plasticity to accommodate the disordered amyloid proteins³⁶.

Lipid raft gangliosides are upstream molecules involved at the very first step in the pathophysiology of PD and AD⁹⁰. AmyP53 targets this earliest step and blocks the neurotoxic Ca^{2+} cascade that is responsible for the neuronal dysfunction and eventual loss in neurodegenerative diseases⁹¹. Most importantly, we demonstrate that AmyP53 efficiently binds to ganglioside GT1b which has a higher affinity for $\text{A}\beta$ than GM1⁴² and represents a key target for AD and potentially for other neurodegenerative therapies including PD⁹⁰. In line with this notion, the protective effects of AmyP53 have been demonstrated on an ex vivo model of AD (hippocampal slices)⁸³ and now in an animal model of PD (Fig. 8). Thus, AmyP53 is the first therapeutic candidate with a dual inhibition function against $\text{A}\beta$ and α -synuclein toxicity. AmyP53 marks a significant milestone for developing disease-modifying therapeutics for the treatment of neurodegenerative diseases. Its unique design opens the route for a series of adaptive peptides against other diseases associated with amyloid proteins and/or IDPs targeting lipid rafts.

To further investigate the therapeutic potential of this peptide in humans, we performed a series of preclinical toxicology and pharmacokinetics studies in rats and rabbits (Table 2), whose raft gangliosides are recognized by AmyP53 (Fig. 9). The design of this peptide excluded any potential toxic domain, in particular the cholesterol binding domain of amyloid proteins that can form annular oligomers by itself as shown for $\text{A}\beta_{22-35}$ ⁹². The safety of AmyP53 treatment was previously demonstrated in several cell culture models⁴⁷ and by initial studies in rats which demonstrated that the maximal tolerated dose of AmyP53 was > 5 mg/kg body weight after a one-week intranasal administration and > 80 mg/kg after a one-week intravenous administration⁴⁸. These data were fully confirmed and extended in new toxicology studies performed in rats (28 days) and rabbits (14 days) (Table 2). The NOAEL for intranasal administration of AmyP53 was > 5 mg/kg in both species, which is several orders of magnitude above the therapeutic doses used in the present study. Indeed, the 50% inhibitory concentration (IC_{50}) of AmyP53 on the formation of Ca^{2+} -permeable oligomeric pores was previously determined to be 30 nM in competition experiments with 220 nM of $\text{A}\beta_{1-42}$ ⁴⁸. These data are consistent with the observation that AmyP53 is able to saturate the lipid raft surface at concentrations significantly lower than α -synuclein (Fig. 1). In this respect, it is important to note that AmyP53 does not target the amyloid protein, but the lipid raft. If AmyP53 can saturate the lipid raft surface at a given concentration, this concentration is expected to be inhibitory for any amyloid protein since none of them displays an affinity for the raft superior to that of AmyP53. In other words, the concentrations of AmyP53 that prevent the formation of $\text{A}\beta_{1-42}$ oligomeric pores should work for all other amyloid proteins, including α -synuclein.

Finally, AmyP53 did not induce any impairment of cardiorespiratory and cognitive functions, and it is not mutagenic as demonstrated by the Ames test. Moreover, AmyP53 efficiently reaches the brain after intranasal

administration, with a half-life of 61 min in rats⁴⁷. These pharmacokinetics data (Table 4) are in line with the high stability of this peptide in plasma, which is probably due to its binding to plasma proteins (Table 3).

Based on the cumulative findings from these preclinical studies, we conclude that AmyP53 is a robust alternative to any other potential treatment for PD and related synucleopathies. Moreover, since the AmyP53 formula is based on an amino acid combination of the ganglioside binding domain from α -synuclein and A β ⁴⁰, it can be considered as an α -synuclein/A β combination therapy in a single molecule. This property is not anecdotal because it is now becoming obvious that pure neurodegenerative diseases are rather rare. Instead, mixed pathologies (also referred to as overlapping conditions of co-pathologies) seem to be the rule^{93–96}. Thus, both α -synuclein and A β oligomers are probably involved in the pathogenesis of AD and PD, leading the scientific community to consider that these diseases would need therapies targeting simultaneously each of these proteins⁹⁷. In this respect, AmyP53 fulfills these criteria through its dual target mechanism⁹⁸.

Materials and methods

Materials

The batches of AmyP53 (amino acid sequence KEGVLYVGHHHTK, purity > 98%), used in this study were synthesized by Provepharm (Marseille, France) and Proteogenix (Schiltigheim, France). Stock solutions (up to 200 mg/mL) were prepared in HPLC-grade water and stored at – 20 °C before use. Ganglioside GT1b was purchased from Matreya (State College, PA, USA). Recombinant α -synuclein proteins were purchased from rPeptide (Watkinsville, GA, USA).

Calcium assay

Aged cultured of SH-SY5Y cells (> 10 consecutive passages) were loaded with 5 μ M Fluo-4AM for 30 min in the dark, washed three times with Hanks' Balanced Salt Solution (HBSS) and incubated 30 min at 37 °C. Calcium fluxes were estimated by measuring the variation in cell fluorescence intensity after wild-type or mutant α -synuclein injection (220 nM) into the recording chamber directly above an upright microscope objective (BX51W Olympus, Tokyo, Japan) equipped with an illuminator system MT20 module⁸³. Fluorescence emission at 525 nm was imaged by a digital camera CDD (Hamamatsu ORCA-ER, Hamamatsu, Japan) after fluorescence excitation at 490 nm. Time-lapse images (1 frame/10 s) were collected using the CellR Software (Olympus). Fluorescence intensity was measured from region of interest (ROI) centered on individual cells. Signals were expressed as fluorescence after treatment (F_t) divided by the fluorescence before treatment (F_0) and multiplied by 100. All experiments were performed at 30 °C during 75 min. At the end of the calcium assay, fluorescent images were taken. In each condition, the morphology of cells was traced, the area and the fluorescent intensity were determined using the ImageJ software. Then, the ratio area/fluorescence was determined for each cell and averaged for each condition. All experiments were performed in triplicate.

Plasma stability of AmyP53 in rat, rabbit, mini-pig, and dog plasma

400 μ L of dipotassium ethylene diamine tetraacetic Acid (K2-EDTA) plasma from male animals of the indicated species were incubated with AmyP53 (1 μ M) or Propantheline bromide (1 μ M) used as control. The times varied between 0 and 4 h. At the end of each incubation, 2-fold volume of cold acetonitrile with internal standard (100 ng/mL phenacetin) was added to the samples which were immediately analyzed by LC-MS/MS on a Waters Acquity UPLC + Waters TQXS Triple Quadrupole MS using a Waters Acquity HSS T3 (2.1 \times 50 mm, 1.8 μ m) column with pre-column guard filter.

Plasma protein binding of AmyP53 in rat, rabbit, mini-pig and dog by rapid equilibration dialysis (RED)

400 μ L of K2-EDTA plasma from male animals of the indicated species were incubated for 2 h at 37 °C with AmyP53 (5 μ M) or Propanolol (1 μ M) used as control. Samples were analyzed on LC-MS/MS as described above. The unbound fraction was calculated from the response (ratio of analyte peak area to internal standard peak area) obtained for each matrix:

$$Fu = \frac{A_{receiver}}{A_{donor}}$$

$A_{receiver}$ is the analyte response in the sample collected from the receiver side and A_{donor} is the analyte response in the sample collected from the donor side.

Recovery of the experiment was calculated as follows:

$$Recovery\% = 100 \times \frac{A_{receiver} \times V_{receiver} + A_{donor} \times V_{donor}}{A_{recovery} \times V_{donor}}$$

V_{donor} and $V_{receiver}$ are the volumes of the donor side matrix (200 μ L) and the receiver side matrix (350 μ L) in the RED experiment, respectively. $A_{recovery}$ is the analyte response in the recovery sample. The recovery sample was prepared by pooling the remaining amounts of spiked donor side matrices (replicates) together and preparing these for analysis in the same manner as donor side samples. The sample was prepared for analysis immediately after starting the RED experiment⁹⁹.

Animal model of PD

Animals

All experiments were performed by Neuro-Sys (Gardanne, France) under the reference ARE22.01 W in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and followed current European Union regulations (Directive 2010/63/EU). Agreement number : A1301337. C57BL/6 mice were being provided by Janvier Labs (Le Genest-Saint-Isle, France).

α -synuclein protofibril Preparation

Human α -synuclein (stock at 69 μ M in water) was reconstituted at 50 μ M in NaCl, 0.9% (final concentration) and incubated at + 37 °C for 3 days. A typical preparation includes monomeric form (20%), small oligomers (from 25 to 100 kDa; 50%) and large oligomers/fibrils (higher than 100 kDa; 30%)⁵¹.

Stereotaxic injections of α -synuclein protofibrils and AmyP53 treatment

Human α -synuclein protein (stock at 69 μ M in water at -20 °C) was reconstituted at 50 μ M in NaCl, 0.9% (final concentration). A specific preparation was made for the group treated with AmyP53: human α -synuclein was reconstituted at 50 μ M in NaCl, 0.9%, containing AmyP53 (100 μ M final concentration). Mice were subjected to surgery and received 2.5 μ L of α -synuclein solution. Mice were anesthetized by isoflurane (4%, for induction), in an induction chamber coupled with a vaporizer and to an oxygen concentrator. Mice were placed on the stereotaxic frame. Anesthesia was maintained by isoflurane (2%) with a face mask coupled to the isoflurane vaporizer and oxygen concentrator machine. Skull was exposed, and holes were drilled. Mice from group 3 were injected with a preparation containing α -synuclein (50 μ M) and AmyP53 (100 μ M). In this group, the intracerebral administration of AmyP53 was followed by daily treatment of the mice by the intranasal route. The α -synuclein preparations were bilaterally injected into the SNpc, at the following coordinates: A-P, - 0.3 cm; M-L, \pm 0.12 cm; D-V, - 0.45 cm⁵¹. Depth of anesthesia and rectal temperature were verified every 5 min. After surgery, mice were allowed to recover before being placed back in the cage. The animals in vehicle-treated groups were injected with saline. The safety of AmyP53 was assessed, in a preliminary step, in 5 young mice (4-month-old).

Tissue collection for immunostaining

At the end of the experiment (on day 35 post-surgery), mice were deeply anesthetized and perfused with cold phosphate buffered saline (PBS) (3 min), and cold paraformaldehyde (PFA) 4% in PBS (3 min). Immunostaining was performed with $n = 5$ /group. Brains were dissected and further fixed in PFA 4%, overnight at 4 °C, and cryoprotected in 30% sucrose in Tris-phosphate saline (TBS) solution at 4 °C. Coronal sections, including the SNpc, of 40 μ m thickness were cut using a cryostat (4 sections per mouse, each 100 μ m apart). For immunostaining, free-floating sections were incubated in TBS with 0.25% bovine serum albumin, 0.3% Triton X-100 and 1% goat serum, for 1 h at room temperature. 4 brain sections per animal were processed and incubated for 2 h at room temperature with chicken polyclonal anti-tyrosine hydroxylase antibodies (1/1000). These antibodies were revealed with Alexa Fluor 568 anti-chicken IgG, at the dilution 1/500, in TBS with 0.25% donkey serum albumin, 0.3% Triton X-100 and 1% goat serum. Images for quantification (Fig. 8E) were acquired with a confocal microscope LSM 900 with ZEN software at 20x magnification (Zeiss) using the same acquisition parameters (automatic acquisition). The following read-outs were measured: (i) number of TH positive cells in the SNpc, (ii) intensity of TH staining. Images of larger brain slices (Fig. 8A–C) were scanned on a Zeiss LSM 980 confocal microscope using the ZEN 3.5 software. The images were acquired using a Plan-Apochromat 20x/0.8 M27 objective (stacks of 17–18 images were captured with an interval of 1.5 μ m, and an optical zoom of 1). Full pictures were assembled using the orthogonal projection of the ZEN software. Then the different tiles were fused using the “fuse tile” option with a minimal overlap of 10 and a maximal shift of 20.

Molecular modeling simulations

AmyP53 was modeled de novo using the software HyperChem⁴⁰. The Charmm topology and parameters of AmyP53 were generated using the tool “Automatic PSF Builder” on VMD software¹⁰⁰. The coordinates and the topology of cholesterol (CLR) and GT1b constituting the cluster GT1b/CLR. The lipid bilayer composed by 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC) and CLR in ratio 1:1 was built using the tool “Bilayer Builder” available on CHARMM-GUI^{101,102}. Each element was merged to create our system which consists of AmyP53 and the α -synuclein placed at 12 Å above the surface of the lipid raft inserted in a POPC bilayer. Finally, the system was solubilized with TIP3P water model and neutralized with the addition of Na⁺ and Cl⁻ ions at a final concentration of 0.15 mol/L using the tools “Add solvation box” and “Add ions” supported by the software VMD. The system was simulated using the software NAMD 2.14 for Windows 10 coupled with the force field CHARMM36m^{103,104}. The system was minimized for 10,000 steps to remove all bad contact between atoms and equilibrated at constant temperature (310 K) and constant pressure (1 atm) for 5 ns with constraint on the peptide followed by 5 ns with constraint on the peptide backbone, then, productions runs were performed.

Monolayers studies

AmyP53-ganglioside and α -synuclein-ganglioside interactions were studied with the Langmuir film balance technique with a fully automated microtensiometer (μ TROUGH SX, Kibron Inc. Helsinki, Finland). The interaction of a peptide (or a protein) with a ganglioside monolayer is an interfacial phenomenon which can be studied by surface pressure (π) measurements¹⁰⁵. The interaction of a protein with a ganglioside monolayer can be detected, at constant area, by an increase in the surface pressure ($\Delta\pi$). This increase is caused by the insertion of the protein between the polar heads of vicinal gangliosides, which is not counterbalanced by an increase of the area of the monolayer. This effect can be followed kinetically by real-time surface pressure measurements

after injecting the protein into the aqueous subphase underneath the ganglioside monolayer (or gangliosides extracted from animal brains) as described previously¹⁰⁶. The initial velocity of the insertion process is expressed as $\text{mN}\cdot\text{m}^{-1}\cdot\text{min}^{-1}$. A logistic curve fitting [$f(x) = 1/(1 + e^{-x})$] has been done with the OriginPro software (OriginLab, Northampton, MA, USA).

Ganglioside extraction and quantitation

Gangliosides extracted from rat and rabbit brains and human red blood cells were recovered from the upper phase of a Folch partition as previously described⁸³.

Toxicology studies in rats and rabbits

The regulatory toxicology studies of AmyP53 in rats and rabbits were performed by independent CROs (Etap-Lab, Vandoeuvre-lès-Nancy, France; Area Produttiva-Roma, Italia; Vivotecnica, Madrid, Spain) under good laboratory practice (GLP) conditions with the authorization of French, Spanish and Italian health agencies. Methods, route of administration and doses are summarized in Table 1. Rats that completed the scheduled test period were euthanized by carbon dioxide. Rabbits that completed the scheduled test period were sedated (Dorbene Vet[®]) and killed by intravenous injection of a suitable agent (Tanax[®]). The intranasal and intravenous administration of AmyP53 for the pharmacokinetics studies were performed by Syncrosome (Marseille, France)⁴⁷. Cardiorespiratory studies in rats were performed by ERBC (Baugy, France).

Statistical analysis

The statistical significance was tested using Student's t-test or One-Way ANOVA with post-hoc T-tests.

Ethical statements

This study is reported in accordance with ARRIVE guidelines (<https://arriveguidelines.org>). The experimental protocols for toxicology studies in rats were approved by the Ethics Committee on Animal Experimentation of Vivotecnica that promotes the use of alternative methods, the reduction in the number of animals used and the refinement in the experimental protocols applied. The experimental protocols for toxicology studies in rabbits were approved by the Ethics Committee of ERBC according to European regulations on the protection of animals used for scientific purposes and fully accredited by AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care). Animal welfare Procedures and facilities were compliant with the requirements of the Directive 2010/63/EU on the protection of animals used for scientific purposes. The national transposition of the Directive is defined in Decreto Legislativo 26/2014. ERBC test facility is fully accredited by AAALAC. Aspects of the protocol concerning animal welfare have been approved by ERBC animal-welfare body. For the in vivo mouse model of PD (Neuro-Sys), experiments were carried out in accordance with the National Research Council (US) Guide for the Care and Use of Laboratory Animals and followed current European Union regulations (Directive 2010/63/EU). The agreement number for the use of laboratory animals is A1301337 (in vivo mouse model of Parkinson's disease).

Data availability

Data is provided within the manuscript.

Received: 22 October 2024; Accepted: 12 March 2025

Published online: 17 March 2025

References

- Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: A review. *Jama* **323**(6), 548–560 (2020).
- Dorsey, E. et al. The emerging evidence of the Parkinson pandemic. *J. Parkinsons Dis.* **8**(s1), S3–S8 (2018).
- Rossi, A. et al. Projection of the prevalence of Parkinson's disease in the coming decades: Revisited. *Mov. Disord.* **33**(1), 156–159 (2018).
- Vijiaratnam, N. et al. Progress towards therapies for disease modification in Parkinson's disease. *Lancet Neurol.* **20**(7), 559–572 (2021).
- McFarthing, K. et al. Parkinson's disease drug therapies in the clinical trial pipeline: 2023 update. *J. Parkinsons Dis.* **13**(4), 427–439 (2023).
- Charvin, D. et al. Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. *Nat. Rev. Drug Discov.* **17**(11), 804–822 (2018).
- Elkouzi, A. et al. Emerging therapies in Parkinson disease—repurposed drugs and new approaches. *Nat. Rev. Neurol.* **15**(4), 204–223 (2019).
- Fields, C. R., Bengoa-Vergniory, N. & Wade-Martins, R. Targeting alpha-synuclein as a therapy for Parkinson's disease. *Front. Mol. Neurosci.* **12**, 299 (2019).
- Brundin, P., Dave, K. D. & Kordower, J. H. Therapeutic approaches to target alpha-synuclein pathology. *Exp. Neurol.* **298**, 225–235 (2017).
- Menon, S. et al. Alpha-synuclein targeting therapeutics for Parkinson's disease and related synucleinopathies. *Front. Neurol.* **13**, 852003 (2022).
- Galvagnion, C. The role of lipids interacting with α -synuclein in the pathogenesis of Parkinson's disease. *J. Parkinsons Dis.* **7**(3), 433–450 (2017).
- Maroteaux, L., Campanelli, J. T. & Scheller, R. H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. *J. Neurosci.* **8**(8), 2804–2815 (1988).
- Cooper, A. A. et al. α -Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. *Science* **313**(5785), 324–328 (2006).
- Burré, J. The synaptic function of α -synuclein. *J. Parkinsons Dis.* **5**(4), 699–713 (2015).
- Vekrellis, K. & Stefanis, L. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. *Expert Opin. Ther. Targets* **16**(4), 421–432 (2012).

16. Tsigelny, I. F. et al. Role of α -synuclein penetration into the membrane in the mechanisms of oligomer pore formation. *Febs J.* **279**(6), 1000–1013 (2012).
17. Schmidt, F. et al. Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α -synuclein oligomers in lipid membranes. *PLoS One.* **7**(8), e42545 (2012).
18. Yahi, N. et al. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α -synuclein oligomers in Parkinson's disease. *Glycoconj. J.* 1–11 (2021).
19. Quist, A. et al. Amyloid ion channels: A common structural link for protein-misfolding disease. *Proc. Natl. Acad. Sci. U. S. A.* **102**(30), 10427–10432 (2005).
20. Lashuel, H. A. et al. Neurodegenerative disease: Amyloid pores from pathogenic mutations. *Nature* **418**(6895), 291 (2002).
21. Uversky, V. N. A protein-chameleon: Conformational plasticity of α -synuclein, a disordered protein involved in neurodegenerative disorders. *J. Biomol. Struct. Dyn.* **21**(2), 211–234 (2003).
22. Uversky, V. N. Intrinsically disordered proteins and their environment: Effects of strong denaturants, temperature, pH, counter ions, membranes, binding partners, osmolytes, and macromolecular crowding. *Protein J.* **28**(7–8), 305–325 (2009).
23. Uversky, V. N. The mysterious unfoldome: Structureless, underappreciated, yet vital part of any given proteome. *J. Biomed. Biotechnol.* **2010**, 568068 (2010).
24. Uversky, V. N. Functional roles of transiently and intrinsically disordered regions within proteins. *FEBS J.* **282**(7), 1182–1189 (2015).
25. Beyer, K. Mechanistic aspects of Parkinson's disease: α -synuclein and the biomembrane. *Cell Biochem. Biophys.* **47**, 285–299 (2007).
26. Das, T. & Eliezer, D. Membrane interactions of intrinsically disordered proteins: The example of α -synuclein. *Biochim. Biophys. Acta BBA Proteins Proteom.* **1867**(10), 879–889 (2019).
27. Tempra, C. et al. A unifying framework for amyloid-mediated membrane damage: The lipid-chaperone hypothesis. *Biochim. Biophys. Acta BBA Proteins Proteom.* **1870**(4), p140767 (2022).
28. Sciacca, M. F. et al. Lipid-chaperone hypothesis: A common molecular mechanism of membrane disruption by intrinsically disordered proteins. *ACS Chem. Neurosci.* **11**(24), 4336–4350 (2020).
29. Pathak, B. K. et al. The role of membranes in function and dysfunction of intrinsically disordered amyloidogenic proteins. *Adv. Protein Chem. Struct. Biol.* **128**, 397–434 (2022).
30. Fantini, J. *Lipid Rafts and Human Diseases: Why We Need To Target Gangliosides* (FEBS Open Bio, 2023).
31. Fusco, G. et al. Structural ensembles of membrane-bound α -synuclein reveal the molecular determinants of synaptic vesicle affinity. *Sci. Rep.* **6**(1), 27125 (2016).
32. Fantini, J. & Yahi, N. Molecular basis for the glycosphingolipid-binding specificity of α -synuclein: Key role of tyrosine 39 in membrane insertion. *J. Mol. Biol.* **408**(4), 654–669 (2011).
33. Fantini, J., Carlus, D. & Yahi, N. The fusogenic Tilted peptide (67–78) of α -synuclein is a cholesterol binding domain. *Biochim. Biophys. Acta* **1808**(10), 2343–2351 (2011).
34. Di Scala, C. et al. Interaction of Alzheimer's β -amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. *Biochemistry* **53**(28), 4489–4502 (2014).
35. Fantini, J. & Yahi, N. The driving force of α -synuclein insertion and amyloid channel formation in the plasma membrane of neural cells: Key role of ganglioside- and cholesterol-binding domains. In *Lipid-Mediated Protein Signal* 15–26 (2013).
36. Azzaz, F. et al. AmyP53 prevents the formation of neurotoxic β -Amyloid oligomers through an unprecedented mechanism of interaction with gangliosides: Insights for Alzheimer's disease therapy. *Int. J. Mol. Sci.* **24**(2), 1760 (2023).
37. Musteikytė, G. et al. Interactions of α -synuclein oligomers with lipid membranes. *Biochim. Biophys. Acta BBA Biomembr.* **1863**(4), 183536 (2021).
38. Suzuki, M. et al. Pathological role of lipid interaction with α -synuclein in Parkinson's disease. *Neurochem. Int.* **119**, 97–106 (2018).
39. Fantini, J., Chahinian, H. & Yahi, N. Progress toward Alzheimer's disease treatment: leveraging the Achilles' heel of A β oligomers?. *Protein Sci.* **29**(8), 1748–1759 (2020).
40. Yahi, N. & Fantini, J. Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding peptide. *PLoS One* **9**(8), e104751 (2014).
41. Matsuzaki, K. A β -ganglioside interactions in the pathogenesis of Alzheimer's disease. *Biochim. Biophys. Acta BBA Biomembr.* **1862**(8), 183233 (2020).
42. Ariga, T. et al. Characterization of High-Affinity binding between gangliosides and amyloid β -Protein. *Arch. Biochem. Biophys.* **388**(2), 225–230 (2001).
43. Di Pasquale, E. et al. Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of α -synuclein is corrected by GM3 but not by GM1 gangliosides. *J. Mol. Biol.* **397**(1), 202–218 (2010).
44. Martinez, Z. et al. GM1 specifically interacts with α -synuclein and inhibits fibrillation. *Biochemistry* **46**(7), 1868–1877 (2007).
45. Gaspar, R. et al. Ganglioside lipids accelerate α -synuclein amyloid formation. *Biochim. Biophys. Acta BBA Proteins Proteom.* **1866**(10), 1062–1072 (2018).
46. Fridolf, S. et al. Ganglioside GM3 stimulates lipid-protein co-assembly in α -synuclein amyloid formation. *Biophys. Chem.* **293**, 106934 (2023).
47. Di Scala, C. et al. AmyP53, a therapeutic peptide candidate for the treatment of Alzheimer's and Parkinson's disease: Safety, stability, pharmacokinetics parameters and nose-to brain delivery. *Int. J. Mol. Sci.* **23**(21), 13383 (2022).
48. El-Battari, A. et al. Gene therapy strategy for Alzheimer's and Parkinson's diseases aimed at preventing the formation of neurotoxic oligomers in SH-SY5Y cells. *Int. J. Mol. Sci.* **22**(21), 11550 (2021).
49. Flores, A. et al. Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B. *Proc. Natl. Acad. Sci. U. S. A.* **116**(36), 18098–18108 (2019).
50. Urry, D. W. et al. Circular dichroism and absorption of the polytetrapeptide of Elastin: A polymer model for the beta-turn. *Biochem. Biophys. Res. Commun.* **61**(4), 1427–1433 (1974).
51. Henriques, A. et al. α -Synuclein: The spark that flames dopaminergic neurons, in vitro and in vivo evidence. *Int. J. Mol. Sci.* **23**(17), 9864 (2022).
52. Roux, S., Sablé, E. & Porsolt, R. D. Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function. *Curr. Protoc. Pharmacol.* (2005).
53. Ackerman, G. A., Wolken, K. W. & Gelder, F. B. Surface distribution of monosialoganglioside GM1 on human blood cells and the effect of exogenous GM1 and neuraminidase on cholera toxin surface labeling. A quantitative immunocytochemical study. *J. Histochem. Cytochem.* **28**(10), 1100–1112 (1980).
54. Ando, S. & YAMAKAWA, T. Separation of Polar glycolipids from human red blood cells with special reference to blood Group-A activit. *J. Biochem.* **73**(2), 387–396 (1973).
55. Thompson, C. et al. Modified bacterial mutation test procedures for evaluation of peptides and amino acid-containing material. *Mutagenesis* **20**(5), 345–350 (2005).
56. Guay, D. R. Clinical pharmacokinetics of drugs used to treat urge incontinence. *Clin. Pharmacokinet.* **42**(14), 1243–1285 (2003).
57. Kontermann, R. E. Half-life extended biotherapeutics. *Expert Opin. Biol. Ther.* **16**(7), 903–915 (2016).
58. Zaman, R. et al. Current strategies in extending half-lives of therapeutic proteins. *J. Control Release.* **301**, 176–189 (2019).
59. Pollaro, L. & Heinis, C. Strategies to prolong the plasma residence time of peptide drugs. *MedChemComm* **1**(5), 319–324 (2010).

60. Park, M. J. et al. Elevated levels of α -synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. *J. Clin. Neurol.* **7**(4), 215–222 (2011).
61. Tokuda, T. et al. Detection of elevated levels of α -synuclein oligomers in CSF from patients with Parkinson disease. *Neurology* **75**(20), 1766–1772 (2010).
62. George, J. M. et al. Characterization of a novel protein regulated during the critical period for song learning in the zebra Finch. *Neuron* **15**(2), 361–372 (1995).
63. Abeliovich, A. et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. *Neuron* **25**(1), 239–252 (2000).
64. Cabin, D. E. et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. *J. Neurosci.* **22**(20), 8797–8807 (2002).
65. Golovko, M. Y. et al. The role of alpha-synuclein in brain lipid metabolism: A downstream impact on brain inflammatory response. *Mol. Cell. Biochem.* **326**(1–2), 55–66 (2009).
66. Lee, S. J., Jeon, H. & Kandr, K. V. Alpha-synuclein is localized in a subpopulation of rat brain synaptic vesicles. *Acta Neurobiol. Exp.* **68**(4), 509–515 (2008).
67. Murphy, D. D. et al. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. *J. Neurosci.* **20**(9), 3214–3220 (2000).
68. Nemani, V. M. et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle recluster after endocytosis. *Neuron* **65**(1), 66–79 (2010).
69. Outeiro, T. F. & Lindquist, S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. *Science* **302**(5651), 1772–1775 (2003).
70. Willingham, S. et al. Yeast genes that enhance the toxicity of a mutant Huntingtin fragment or alpha-synuclein. *Science* **302**(5651), 1769–1772 (2003).
71. Withers, G. S. et al. Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. *Brain Res. Dev. Brain Res.* **99**(1), 87–94 (1997).
72. Cheng, F., Vivacqua, G. & Yu, S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. *J. Chem. Neuroanat.* **42**(4), 242–248 (2011).
73. Sun, J. et al. Functional Cooperation of α -synuclein and VAMP2 in synaptic vesicle recycling. *Proc. Natl. Acad. Sci.* **116**(23), 11113–11115 (2019).
74. Huang, M. et al. α -Synuclein: A multifunctional player in exocytosis, endocytosis, and vesicle recycling. *Front. NeuroSci.* **13**, 28 (2019).
75. Sharma, M. & Burré, J. α -Synuclein in synaptic function and dysfunction. *Trends Neurosci.* **46**(2), 153–166 (2023).
76. Ruipérez, V., Darios, F. & Davletov, B. Alpha-synuclein, lipids and Parkinson's disease. *Prog. Lipid Res.* **49**(4), 420–428 (2010).
77. Snead, D. & Eliezer, D. Alpha-synuclein function and dysfunction on cellular membranes. *Exp. Neurobiol.* **23**(4), 292 (2014).
78. Kumar, S. T. et al. How specific are the conformation-specific α -synuclein antibodies? Characterization and validation of 16 α -synuclein conformation-specific antibodies using well-characterized preparations of α -synuclein monomers, fibrils and oligomers with distinct structures and morphology. *Neurobiol. Dis.* **146**, 105086 (2020).
79. Escribá, P. V. Membrane-lipid therapy: A historical perspective of membrane-targeted therapies—From lipid bilayer structure to the pathophysiological regulation of cells. *Biochim. Biophys. Acta Biomembr.* **1859**(9 Pt B), 1493–1506 (2017).
80. Pineda, A. & Burré, J. Modulating membrane binding of α -synuclein as a therapeutic strategy. *Proc. Natl. Acad. Sci. U. S. A.* **114**(6), 1223–1225 (2017).
81. Inci, O. K. et al. Gangliosides as therapeutic targets for neurodegenerative diseases. *J. Lipids* 4530255 (2024).
82. Fantini, J. et al. Conformationally adaptive therapeutic peptides for diseases caused by intrinsically disordered proteins (IDPs). New paradigm for drug discovery: Target the target, not the arrow. *Pharmacol. Ther.* **267**, 108797 (2025).
83. Di Scala, C. et al. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides. *Biochim. Biophys. Acta* **1862**(2), 213–222 (2016).
84. Jo, E. et al. Defective membrane interactions of Familial Parkinson's disease mutant A30P alpha-synuclein. *J. Mol. Biol.* **315**(4), 799–807 (2002).
85. Robotta, M. et al. Alpha-Synuclein disease mutations are structurally defective and locally affect membrane binding. *J. Am. Chem. Soc.* **139**(12), 4254–4257 (2017).
86. Pfefferkorn, C. M., Jiang, Z. & Lee, J. C. Biophysics of α -synuclein membrane interactions. *Biochim. Biophys. Acta* **1818**(2), 162–171 (2012).
87. Nusch, B. et al. Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: A thermodynamics study. *J. Biol. Chem.* **279**(21), 21966–21975 (2004).
88. Fantini, J. et al. Lipid rafts: Structure, function and role in HIV, Alzheimer's and prion diseases. *Expert Rev. Mol. Med.* **4**(27), 1–22 (2002).
89. Kubo, S. et al. A combinatorial code for the interaction of α -synuclein with membranes. *J. Biol. Chem.* **280**(36), 31664–31672 (2005).
90. Dukhinova, M. et al. Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer's disease. *Neurobiol. Aging* **77**, 128–143 (2019).
91. Danzer, K. M. et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. *J. Neurosci.* **27**(34), 9220–9232 (2007).
92. Di Scala, C. et al. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β -amyloid peptide. *J. Neurochem.* **128**(1), 186–195 (2014).
93. Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. *Brain* **141**(7), 2181–2193 (2018).
94. Compta, Y. & Revesz, T. Neuropathological and biomarker findings in Parkinson's disease and Alzheimer's disease: From protein aggregates to synaptic dysfunction. *J. Parkinsons Dis.* **11**(1), 107–121 (2021).
95. Biundo, R. et al. The contribution of beta-amyloid to dementia in lewy body diseases: A 1-year follow-up study. *Brain Commun.* **3**(3), fcb180 (2021).
96. Kim, J. R. Oligomerization by co-assembly of β -amyloid and α -synuclein. *Front. Mol. Biosci.* **10**, 1153839 (2023).
97. Lashuel, H. A. Rethinking protein aggregation and drug discovery in neurodegenerative diseases: Why we need to embrace complexity? *Curr. Opin. Chem. Biol.* **64**, 67–75 (2021).
98. Di Scala, C. et al. Common molecular mechanism of amyloid pore formation by Alzheimer's β -amyloid peptide and α -synuclein. *Sci. Rep.* **6**(1), 28781 (2016).
99. Waters, N. J. et al. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. *J. Pharm. Sci.* **97**(10), 4586–4595 (2008).
100. Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. *J. Mol. Graph.* **14**(1), 33–38 (1996).
101. Wu, E. L. et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. *J. Comput. Chem.* **35**(27), 1997–2004 (2014).
102. Jo, S. et al. CHARMM-GUI: a web-based graphical user interface for CHARMM. *J. Comput. Chem.* **29**(11), 1859–1865 (2008).
103. Phillips, J. C. et al. Scalable molecular dynamics with NAMD. *J. Comput. Chem.* **26**(16), 1781–1802 (2005).

104. Huang, J. et al. CHARMM36m: An improved force field for folded and intrinsically disordered proteins. *Nat. Methods* **14**(1), 71–73 (2017).
105. Thakur, G., Micic, M. & Leblanc, R. M. Surface chemistry of Alzheimer's disease: A Langmuir monolayer approach. *Colloids Surf. B* **74**(2), 436–456 (2009).
106. Di Scala, C. & Fantini, J. Hybrid in silico/in vitro approaches for the identification of functional cholesterol-binding domains in membrane proteins. *Methods Mol. Biol.* **1583**, 7–19 (2017).

Acknowledgements

We thank Etap-Lab (Vandoeuvre-lès-Nancy, France), Syncrosome (Marseille, France), Neuro-Sys (Gardanne, France), ERBC (Baugy, France and Pomezia, RM Italy) and Vivotecnia (Madrid, Spain) for the animal studies. We also thank Centaur Clinical (Gardanne, France) for the genotoxicity assay and Alessandra Flores, Christian Leveque and Oussama El Far for their help in the circular dichroism studies.

Author contributions

A.A., F.A., H.C., J.F. and N.Y. analyzed and interpreted the data and participated in the writing of the manuscript. More specifically, F.A. performed the molecular modelling studies and A.A. analyzed the immunolabelled brain slices of the animal model. All authors have read and agreed to the published version of the manuscript.

Declarations

Competing interests

N.Y. and J.F. are co-inventors of the AmyP53 peptide (patent Application EP15709163.8 A), currently under development for the treatment of Alzheimer's and Parkinson's diseases by the AmyPore company. H.C. is president of the Ethics and Scientific Committee of AmyPore. A.A. is the project leader of AmyPore. F.A. does not have any conflict of interest. All other authors have no competing interest.

Additional information

Correspondence and requests for materials should be addressed to J.F.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2025